Floatz logo

Poly-Iclc

Metastatic Melanoma

University of Southern Californianucleic_acidPhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

99 Active assets in the Metastatic Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Montanide Isa 51
Ludwig Institute for Cancer Research
Phase 2BB

View all 50 →

Same molecule, other indications

Poly-Iclc is also rated in:

melanomaActive
B
Indicative · Phase 2
63 / 100
View asset →
ocular melanomaDormant
B
Indicative · Phase 2
63 / 100
View asset →
mucosal melanomaActive
B
Indicative · Phase 2
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →